home / stock / adgi / adgi quote
Last: | $4.64 |
---|---|
Change Percent: | -0.43% |
Open: | $4.62 |
Close: | $4.64 |
High: | $4.74 |
Low: | $4.4 |
Volume: | 535,536 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.64 | $4.62 | $4.64 | $4.74 | $4.4 | 535,536 | 09-12-2022 |
$4.6 | $4.64 | $4.6 | $4.645 | $4.46 | 370,835 | 09-09-2022 |
$4.63 | $4.59 | $4.63 | $4.77 | $4.5 | 474,300 | 09-08-2022 |
$4.61 | $4.47 | $4.61 | $4.82 | $4.46 | 675,357 | 09-07-2022 |
$4.55 | $4.78 | $4.55 | $4.8 | $4.53 | 496,848 | 09-06-2022 |
$4.78 | $4.71 | $4.78 | $4.84 | $4.65 | 337,873 | 09-02-2022 |
$4.63 | $4.57 | $4.63 | $4.65 | $4.41 | 351,009 | 09-01-2022 |
$4.56 | $4.5 | $4.56 | $4.685 | $4.46 | 264,625 | 08-31-2022 |
$4.48 | $4.65 | $4.48 | $4.66 | $4.42 | 240,968 | 08-30-2022 |
$4.61 | $4.51 | $4.61 | $4.81 | $4.51 | 293,440 | 08-29-2022 |
$4.59 | $4.65 | $4.59 | $4.75 | $4.535 | 373,940 | 08-26-2022 |
$4.67 | $4.76 | $4.67 | $4.84 | $4.56 | 499,431 | 08-25-2022 |
$4.77 | $4.42 | $4.77 | $4.88 | $4.3967 | 642,928 | 08-24-2022 |
$4.48 | $4.16 | $4.48 | $4.51 | $3.8953 | 444,655 | 08-23-2022 |
$4.17 | $4.6 | $4.17 | $4.9 | $4.09 | 1,367,666 | 08-22-2022 |
$4.2 | $4.4 | $4.2 | $4.77 | $4.195 | 1,375,848 | 08-19-2022 |
$4.51 | $4.03 | $4.51 | $4.55 | $3.86 | 2,415,452 | 08-18-2022 |
$4.02 | $3.8 | $4.02 | $4.17 | $3.8 | 2,691,292 | 08-17-2022 |
$3.89 | $3.93 | $3.89 | $3.95 | $3.75 | 369,347 | 08-16-2022 |
$3.99 | $4 | $3.99 | $4.09 | $3.9238 | 585,135 | 08-15-2022 |
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise PEMGARDA product availability in the U.S. anticipated i...
Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development work Today’s update on Day 67 and Day 90 event rates is the first of two planned publ...
PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive immunobridging data and on safety data from the CANOPY clinical trial along with ongoing in vitro ...